Literature DB >> 8358152

Mode of interaction between platelet factor 4 and heparin.

M Maccarana1, U Lindahl.   

Abstract

Platelet factor 4 (PF4) is a platelet-derived protein capable of binding to, and thus neutralizing, the biological activities of heparin and heparan sulphate. The mode of binding of PF4 to heparin was investigated in a comparative study also involving antithrombin (AT; previously shown to selectively bind a specific oligosaccharide sequence) and fibronectin (FN; non-specific electrostatic interaction). Heparin-derived saccharides were incubated with each of the three proteins, followed by separation of free and protein-bound carbohydrate on a nitrocellulose filter. The interaction systems involved either (i) competition for the protein ligand between 3H-labelled heparin and unlabelled, size-fractionated heparin oligosaccharides (isolated after deaminative cleavage with HNO2) or (ii) direct binding of 3H-labelled oligosaccharides. Species smaller than octasaccharides were unable to bind AT, whereas binding to FN and PF4 increased continuously throughout the series, with increasing size of the oligosaccharides. Further separation by anion-exchange chromatography showed that the PF4-binding and FN-binding octasaccharides represented essentially all components present in the initial octasaccharide fraction, the proportion of binding species increasing with charge (hence with the degree of sulphation). The AT-binding octasaccharides, on the other hand, selectively represented only a few of the total octasaccharide components, without any correlation to overall charge. These results indicate that the binding of PF4 to heparin occurs by relatively non-specific electrostatic interactions. The methodology delineated here may be generally useful in assessing specificity in glycosaminoglycan-protein interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358152     DOI: 10.1093/glycob/3.3.271

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  25 in total

Review 1.  Intracellular proteoglycans.

Authors:  Svein Olav Kolset; Kristian Prydz; Gunnar Pejler
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

2.  The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.

Authors:  Eduard Condac; Heather Strachan; Gerardo Gutierrez-Sanchez; Benjamin Brainard; Christina Giese; Christian Heiss; Darryl Johnson; Parastoo Azadi; Carl Bergmann; Ron Orlando; Charles T Esmon; Job Harenberg; Kelley Moremen; Lianchun Wang
Journal:  Glycobiology       Date:  2012-05-28       Impact factor: 4.313

3.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

4.  Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.

Authors:  Yongmei Xu; Elizabeth H Pempe; Jian Liu
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

5.  Isolation and functional analysis of syndecans.

Authors:  Pyong Woo Park
Journal:  Methods Cell Biol       Date:  2017-10-06       Impact factor: 1.441

6.  Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

7.  Capillary zone electrophoresis for the study of the binding of antithrombin to low-affinity heparin.

Authors:  K Gunnarsson; L Valtcheva; S Hjertén
Journal:  Glycoconj J       Date:  1997-11       Impact factor: 2.916

8.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

9.  Severe bleeding secondary to misuse of fondaparinux: a case report.

Authors:  Hubert Nielly; Aurore Bousquet; Patrick Le Garlantezec; Eric Perrier; Xavier Bohand
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 10.  Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules.

Authors:  M Salmivirta; M Jalkanen
Journal:  Experientia       Date:  1995-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.